ELI LILLY & CO (LLY)       340.5  -1.6 (-0.47%)

340.5  -1.6 (-0.47%)

US5324571083 - Common Stock - After market: 340 -0.5 (-0.15%)

ELI LILLY & CO340.5

NYSE:LLY (1/30/2023, 7:06:42 PM)-1.6 (-0.47%)

After market: 340 -0.5 (-0.15%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-02 2023-02-02
Ins Owners 10.56% Inst Owners 80.23%
Market Cap 336.12B Shares 987.12M
PE 40.11 Fwd PE 36.85
Dividend Yield 1.31% Analysts 80
IPO 07-09 1970-07-09

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000.0

CEO: David A. Ricks

Employees: 35000

Website: https://www.lilly.com/

LLY News

News Image11 hours ago - The Motley FoolDown 14.5%, Is Pfizer Stock a Screaming Buy?

Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.

News Image12 hours ago - Market News VideoAnalyst Favorites With Strong Buyback Activity: Eli Lilly Ranks As a Top PickNews Imagea day ago - MarketBeatCassava Sciences Stock Undervalued with Its $124 Price Target?

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

News Image3 days ago - Seeking AlphaEli Lilly wins FDA accelerated approval for lymphoma therapy (NYSE:LLY)

Eli Lilly (LLY) announced Friday the FDA cleared its BTK inhibitor Jaypirca as a late-line option for certain patients with rare blood cancer mantle cell lymphoma. Read the full story here.

News Image4 days ago - Yahoo FinanceUPDATE 1-FDA approves Eli Lilly's blood cancer drug

Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer. The Food and Drug Administration gave accelerated approval to Jaypirca for the treatment of adults mantle cell lymphoma after at least two lines of therapy.

News Image4 days ago - Eli Lilly and CompanyU.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor

/PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that the U.S. Food and Drug Administration (FDA) approved...

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example